final pathology. Figure 1 CT of the face, neck, and torso, and PET/CT showing FDG uptake. CT of the chest with contrast (A) reveals a large mass surrounding the distal esophagus measuring 6.0 x 3.7 cm and extending to the gastroesophageal
Search Results
Rajinder S. Grover, Kemp Kernstine, and Amrita Krishnan
Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh
. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet 1997 ; 6 : 1383 – 1387 . 3 Starink TM Hausman R . The cutaneous pathology of extrafacial lesions in Cowden's disease . J Cutan Pathol 1984 ; 11 : 338
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes
suspected uterine neoplasms, the initial evaluation/workup includes a history and physical examination, endometrial biopsy, and other studies (see UN-1, page 250). 7 An expert pathology review will determine whether a patient has either 1) a malignant
Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes
pathology report noted features of ganglioglioma with mixed neuronal and glial growth patterns. In regions of the tumor with an abundant glial component, there was evidence of moderate cell proliferation as assessed by Ki-67 (MIB-1) immunohistochemistry (A
Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda
. Pathology revealed omentum with acute inflammation and abscess formation, with no evidence of malignancy in 13 lymph nodes. He recovered from surgery and was discontinued from the trial, but continued on single-agent dabrafenib due to the BRAF V600E
Katy K. Tsai, Neharika Khurana, Timothy McCalmont, Adil Daud, Boris Bastian, and Iwei Yeh
resected in late April 2015, with pathology indicating poorly differentiated clear cell carcinoma ( Figure 1 ). The tumor was 9.8 cm in greatest diameter and was excised with a positive margin. Focal perineural invasion and vaguely squamoid areas were also
Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, and Pratik Multani
It is not surprising that the molecular pathogenesis of NETs remains elusive with this degree of clinical heterogeneity. Many investigations into the tumorigenesis of NETs have focused on SI-NETs and PNETs, but their molecular pathology is still
Brian J. Williams, Daniel M.S. Raper, Erin Godbout, T. David Bourne, Daniel M. Prevedello, Amin B. Kassam, and Deric M. Park
against chordoma. 46 Finally, brachyury, a histologic marker for chordoma, may also drive chordoma pathology. Transient genetic knockdown of brachyury in chordoma cells was found to induce differentiation and senescence. 47 Furthermore, brachyury has
M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz
her tumor 3 weeks after discontinuing imatinib. Because of the location of the tumor and involvement of the SMV, a Whipple procedure was required. However, it was believed that the neoadjuvant imatinib made this procedure possible. Pathology revealed a
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
, HER2 tumor status determination, and pathology review. Use of MRI is optional and is not universally recommended by experts in the field. Breast MRI advocates note its high sensitivity for evaluation of extent of disease, particularly for invasive
